These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36365147)

  • 1. The Translational Landscape Revealed the Sequential Treatment Containing ATRA plus PI3K/AKT Inhibitors as an Efficient Strategy for AML Therapy.
    Wang K; Ou Z; Deng G; Li S; Su J; Xu Y; Zhou R; Hu W; Chen F
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
    Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
    Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway.
    Huang A; Zeng P; Li Y; Lu W; Lai Y
    Front Oncol; 2021; 11():782065. PubMed ID: 34820336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.
    Cai D; Wang Y; Ottmann OG; Barth PJ; Neubauer A; Burchert A
    Blood; 2006 Mar; 107(5):2094-7. PubMed ID: 16304046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
    Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
    Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
    Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
    Wang R; Xia L; Gabrilove J; Waxman S; Jing Y
    Clin Cancer Res; 2016 Mar; 22(5):1211-21. PubMed ID: 26459180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
    Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Zhang XW; Shen X; Long WY; Xiao H; Li FJ; Xing S; Xiong GL; Yu ZY; Cong YW
    Int J Hematol; 2021 Feb; 113(2):254-262. PubMed ID: 33074481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Stengel S; Petrie KR; Sbirkov Y; Stanko C; Ghazvini Zadegan F; Gil V; Skopek R; Kamiński P; Szymański Ł; Brioli A; Zelent A; Schenk T
    Br J Haematol; 2022 Jul; 198(2):338-348. PubMed ID: 35468223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
    Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
    Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
    Zhang R; Banik NL; Ray SK
    Neurochem Res; 2007 Dec; 32(12):2194-202. PubMed ID: 17616812
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Nguyen CH; Grandits AM; Vassiliou GS; Staber PB; Heller G; Wieser R
    Biomedicines; 2020 Sep; 8(10):. PubMed ID: 32998330
    [No Abstract]   [Full Text] [Related]  

  • 18. Trametinib enhances ATRA-induced differentiation in AML cells.
    Lu H; Li ZY; Ding M; Liang C; Weng XQ; Sheng Y; Wu J; Cai X
    Leuk Lymphoma; 2021 Dec; 62(14):3361-3372. PubMed ID: 34355652
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Nguyen CH; Grandits AM; Purton LE; Sill H; Wieser R
    Cell Cycle; 2020 Oct; 19(20):2573-2588. PubMed ID: 32900260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.